NTRA.US Natera Inc

Healthcare Biotechnology USA Stocks
319.09 USD
Close of Nov 15, 2026
181.00 437.41
Market cap
USD 46.3B
P/E
-
P/B
24.75x
ROE
-15.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NTRA.US undervalued?

Graham number

The Graham number of Natera Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Natera Inc fundamental analysis

No fundamental analysis for Natera Inc yet.

Natera Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Natera Inc

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. T…

Full company profile